Revised Table 2.
Buprenorphine pharmacokinetic parameters
| Parameter (untransformed raw data, Mean ± SD) | PK-2 (2nd Trimester) N = 7 |
PK-3 (3nd Trimester) N = 11 |
PK-P (Postpartum) N = 10 |
p valuei (PK-2:PK-3) | p valueii (½PK-2+½PK-3:PK-P) |
|---|---|---|---|---|---|
| Dose, mg | 8.0 ± 3.1 | 10.0 ± 3.7 | 8.0 ± 0.0 | 0.3333 | 0.0276 |
| Tmax, h | 1.6 ± 2.8 | 1.0 ± 1.1 | 1.9 ± 3.6 | 0.9661 | 0.8411 |
| Dose-normalized Cmax, ng/ml | 0.5 ± 0.1 | 0.5 ± 0.2 | 0.7 ± 0.3 | 0.9964 | 0.0365 |
| Dose-normalized C0, ng/ml | 0.1 ± 0.0 | 0.2 ± 0.2 | 0.3 ± 0.3 | 0.8959 | 0.0032 |
| Dose-normalized C12, ng/ml | 0.1 ± 0.0 | 0.1 ± 0.1 | 0.3 ± 0.3 | 0.1260 | 0.0001 |
| Dose-normalized Cavg, ng/ml | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.3 ± 0.2 | 0.7965 | 0.0068 |
| Dose-normalized AUC, ng* h/mL | 1.9 ± 1.4 | 2.2 ± 1.2 | 4.0 ± 2.5 | 0.7953 | 0.0068 |
Tmax, time to maximum concentration; Dose-norm, Dose-normalized or plasma concentration/dose; Cmax, maximum plasma concentration; C0, time zero trough plasma concentration; C12, twelve-hour plasma concentration; Cavg, average plasma concentration from time zero to twelve-hours; AUC0→12, area under the plasma concentration-time curve from time zero to twelve-hours
*
Data presented as mean ± sd (raw and untransformed)
P-value columns represent comparisons between:
i
2nd vs 3rd trimester: PK-2 vs PK-3
ii
Pregnancy vs Postpartum: the average of PK-2 & PK-3 vs PK-P